Moderna, Inc. (0QF.F)
EUR 37.5
(-3.85%)
EUR 37.5
(-3.85%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -4.71 Billion USD | -156.37% |
| 2022 | 8.36 Billion USD | -31.47% |
| 2021 | 12.2 Billion USD | 1733.33% |
| 2020 | -747.06 Million USD | -45.34% |
| 2019 | -514.02 Million USD | -33.6% |
| 2018 | -384.73 Million USD | -50.34% |
| 2017 | -255.91 Million USD | -18.36% |
| 2016 | -216.21 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -1.17 Billion USD | -641.47% |
| 2024 Q2 | -1.27 Billion USD | -8.85% |
| 2023 Q4 | 217 Million USD | 105.98% |
| 2023 FY | -4.71 Billion USD | -156.37% |
| 2023 Q1 | 79 Million USD | -94.61% |
| 2023 Q2 | -1.38 Billion USD | -1846.84% |
| 2023 Q3 | -3.63 Billion USD | -163.04% |
| 2022 Q3 | 1.04 Billion USD | -52.53% |
| 2022 FY | 8.36 Billion USD | -31.47% |
| 2022 Q2 | 2.19 Billion USD | -39.92% |
| 2022 Q1 | 3.65 Billion USD | -24.88% |
| 2022 Q4 | 1.46 Billion USD | 40.46% |
| 2021 FY | 12.2 Billion USD | 1733.33% |
| 2021 Q3 | 3.33 Billion USD | 19.89% |
| 2021 Q1 | 1.22 Billion USD | 548.1% |
| 2021 Q2 | 2.78 Billion USD | 127.68% |
| 2021 Q4 | 4.86 Billion USD | 46.05% |
| 2020 FY | -747.06 Million USD | -45.34% |
| 2020 Q4 | -272.48 Million USD | -16.63% |
| 2020 Q3 | -233.63 Million USD | -100.18% |
| 2020 Q2 | -116.71 Million USD | 6.05% |
| 2020 Q1 | -124.23 Million USD | 0.01% |
| 2019 FY | -514.02 Million USD | -33.6% |
| 2019 Q1 | -131.12 Million USD | 7.28% |
| 2019 Q2 | -135.05 Million USD | -3.0% |
| 2019 Q3 | -123.19 Million USD | 8.78% |
| 2019 Q4 | -124.24 Million USD | -0.85% |
| 2018 Q3 | -80.33 Million USD | 11.34% |
| 2018 Q4 | -141.42 Million USD | -76.05% |
| 2018 FY | -384.73 Million USD | -50.34% |
| 2018 Q1 | -72.37 Million USD | -90.74% |
| 2018 Q2 | -90.6 Million USD | -25.18% |
| 2017 Q4 | -37.94 Million USD | 0.0% |
| 2017 FY | -255.91 Million USD | -18.36% |
| 2016 FY | -216.21 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| BioNTech SE | 930.3 Million EUR | 606.718% |
| CureVac N.V. | -260.16 Million EUR | -1711.913% |
| Biotest Aktiengesellschaft | 127 Million EUR | 3811.811% |
| Biotest Aktiengesellschaft | 127 Million EUR | 3811.811% |
| BRAIN Biotech AG | -8.27 Million EUR | -56839.244% |
| Formycon AG | 75.79 Million EUR | 6319.408% |
| Heidelberg Pharma AG | -20.34 Million EUR | -23068.62% |
| Medigene AG | -16.17 Million EUR | -29040.137% |